Prostate cancer: The androgen receptor remains front and centre

Nature Reviews Clinical Oncology

Volumn 10, Issue 3, 2013, Pages 126-128

  Saylor, Philip J ^a  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE; ANDROGEN RECEPTOR; CABAZITAXEL; DOCETAXEL; ENZALUTAMIDE; PLACEBO; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ANDROGEN DEPRIVATION THERAPY; ANDROGEN SYNTHESIS; ARTICLE; CANCER SURVIVAL; HUMAN; MALE; METASTASIS; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; TESTOSTERONE BLOOD LEVEL;

ADENOCARCINOMA; ANDROGEN ANTAGONISTS; ANDROGENS; ANDROSTADIENES; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE-FREE SURVIVAL; ENZYME INHIBITORS; HUMANS; MALE; MOLECULAR TARGETED THERAPY; MULTICENTER STUDIES AS TOPIC; NEOPLASM PROTEINS; NEOPLASMS, HORMONE-DEPENDENT; PREDNISONE; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, ANDROGEN; STEROID 17-ALPHA-HYDROXYLASE; SURVIVAL RATE; TAXOIDS;

EID: 84874646083     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2013.14     Document Type: Article

References (9)

1. de Bono, J. S. et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364, 1995-2005 (2011).
2. Ryan, C. J. et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N. Engl. J. Med. 368, 138-148 (2013).
3. Fizazi, K. et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 13, 983-992 (2012).
4. Petrylak, D. P. et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 351, 1513-1520 (2004).
5. Tannock, I. F. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 351, 1502-1512 (2004).
6. Darshan, M. S. et al. Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Res. 71, 6019-6029 (2011).
7. Zhu, M. L. et al. Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res. 70, 7992-8002 (2010).
8. Smith, M. R. Obesity and sex steroids during gonadotropin-releasing hormone agonist treatment for prostate cancer. Clin. Cancer Res. 13, 241-245 (2007).
9. Saylor, P. J. & Smith, M. R. Metabolic complications of androgen deprivation therapy for prostate cancer. J. Urol. 181, 1998-2008 (2009).